Teva announces early tender results of debt tender offer

Teva (TEVA) Pharmaceutical announced the early tender results in connection with its previously announced tender offers as for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: USD 3.150% Senior Notes due 2026, CUSIP 88167AAE1 / ISIN US88167AAE10, issued by Teva Pharmaceutical Finance Netherlands III; USD 4.750% Sustainability-Linked Senior Notes due 2027, CUSIP 88167AAP6 / ISIN US88167AAP66, issued by Teva Pharmaceutical Finance Netherlands III; EUR 3.750% Sustainability-Linked Senior Notes due 2027, Common Code 240660709 / ISIN XS2406607098, issued by Teva Pharmaceutical Finance Netherlands II;USD 7.875% Sustainability-Linked Senior Notes due 2029, CUSIP 88167AAS0 / ISIN US88167AAS06, issued by Teva Pharmaceutical Finance Netherlands III; EUR 7.375% Sustainability-Linked Senior Notes due 2029, Common Code 259280443 / ISIN XS2592804434, issued by Teva Pharmaceutical Finance Netherlands II; and USD 8.125% Sustainability-Linked Senior Notes due 2031, CUSIP 88167AAR2 / ISIN US88167AAR23, issued by Teva Pharmaceutical Finance Netherlands III. As previously announced, Teva increased the Pool 2 Tender Cap and the Pool 3 Tender Cap from $250M to $350M and from $200M to $350M, respectively, in each case representing aggregate cash purchase price. In addition, Teva has exercised its discretion to further increase the pool tender cap for the Pool 3 Notes from $350M to $400M total purchase price. The pool tender caps for the Pool 1 Notes and the Pool 2 Notes will remain unchanged. The combined aggregate purchase price for Notes is increased from $2,250,000,000 to $2,300,000,000. Except as provided above, the terms and conditions of the Offers remain unchanged.